Conferences : [5565]
Collection home page

Conference papers, abstracts, posters, or presentations.

Browse
in this collection
Subscribe to this collection to receive daily e-mail notification of new additions RSS Feed RSS Feed RSS Feed
Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 5565
 next >
PreviewIssue DateTitleAuthor(s)
1-Jul-2023Attitudes and beliefs of Australian cardiologists on the role of seasonal influenza immunisation in cardiovascular care.S R Monagle S.; Spear E.; Thakur U.; Pol D.; Tan S.; Bellamy K. ; Hickman, Joanne ; Jackson B.; Chan J.; Nicholls S.J.; Nelson A.J.
9-Nov-2023Understanding of seasonal influenza immunisation and its cardiovascular benefits among cardiology patients.S R Monagle S.; Spear E.; Thakur U.; Pol D.; Tan S.; Bellamy K. ; Hickman, Joanne ; Jackson B.; Chan J.; Nicholls S.J.; Nelson A.J.
9-Nov-2023The role of seasonal influenza immunisation in cardiovascular care: a survey of cardiologists.S R Monagle S.; Spear E.; Thakur U.; Pol D.; Tan S.; Bellamy K. ; Hickman, Joanne ; Jackson B.; Chan J.; Nicholls S.J.; Nelson A.J.
6-Oct-2024Measuring interaction and influence among health professionals within a huntington's disease clinic: a social network approach.Lie Y.; Mathers S.; Ma H. ; Hosken R.; Stout J.; Mercieca E.; Xu Y.; Phan T.G.
11-Oct-2024Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer.Randall L.; Sukhin V.; Colombo N.; Korach J.; Matsumoto T.; Lalondrelle S.; Vizkeleti J.; Samouelian V.; Salani R.; Salman P.; Nogueira-Rodrigues A.; Ayhan A.; Frentzas S. ; Cueva J.; Kim Y.-M.; Petru E.; Milla D.P.; Sehouli J.; Saevets V.; Yamada K.; Li K.; Szamreta E.; Nguyen A.M.; Pignata S.; Lorusso D.
11-Oct-2024Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study.Marth C.; Moore R.; Bidzinski M.; Pignata S.; Ayhan A.; Rubio M.J.; Beiner M.; Hall M.; Vulsteke C.; Braicu E.I.; Sonoda K.; Wu X.; Frentzas S. ; Mattar A.; McKenzie J.; Yao L.; Khemka V.; Orlowski R.; Gilbert L.; Makker V.
7-Oct-2024Retrospective study of delays in reversal of loop ileostomy-reasons and outcomes during the COVID era.Chen M.; Yoong K.; Liew A.; Weeratunga S.; Tay Y.K.
20-Sep-20241610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig.Armstrong A.J.; Appleman L.J.; Danila D.C.; Lin C.-C.; Lee J.L.; Matsubara N.; Ward P.J.; Pook D.W.; Kim M.; Dorff T.B.; Fischer S.C.; Lin Y.-C.; Horvath L.G.; Sumey C.; Yang Z.; Decato B.E.; Englert J.M.; Smith K.M.; Lolkema M.; Kelly W.K.
20-Sep-20241618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304).Hamid A.A.; Thomas H.; Martin A.; Soon Y.Y.; Horvath L.G.; Zielinski R.; Thomson A.; Tan H.; Sandhu S.K.; Reaume M.N.; Pook D.W.; Parnis F.; McDermott R.S.; Lawrence N.; Frydenberg M. ; Chi K.N.; Stockler M.R.; Davis I.D.; Sweeney C.
20-Sep-20241598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study.Kelly W.K.; Appleman L.J.; Lin C.-C.; Armstrong A.J.; Fischer S.C.; Pook D.W.; Perez Gracia J.L.; Lee J.L.; Berthold D.R.; Ward P.J.; Castellano Gauna D.E.; Horvath L.G.; Kim M.; Matsubara N.; Sumey C.; Shabooti M.; Yang Z.; Connarn J.; Stieglmaier J.; Danila D.C.
20-Sep-2024345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study.Lemech C.; Sun Y.; Nagrial A.; Wu X.; Morris M.; Ning F.; Yang J. ; Pan Y.; Cai J.; Lu P.; Zhang T.; Qiu F.; Hu C.; Zhang M.; Liu Z.; Han G.; Nie J.; Teng C.; Zhou H.; Day D. 
20-Sep-2024684TiP A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors.Keam B.; Ahn J.-H.; Kim K.; Hong S.-H.; Ganju V.; Lim L.E.; Kwatra V.; Body A. ; Rhee P.D.; Jung S.; Yoon J.; Baek E.; Noh Y.S.
20-Sep-2024Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study.Gong J.; Lemech C.; Day D. ; Shan J.; Morris M.; Nagrial A.; Chen M.; Huang X.; Zong H.; Wang N.; Yang Y.; Yi T.; Li W.; Zhuang Z.; Li Z.; Liu Z.; Luo Y.; Zhang Y.; Zhou H.; Shen L.
20-Sep-2024LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG.Leong T.; Smithers B.M.; Michael M.; Haustermans K.M.; Wong R.; Gebski V.; O'Connell R.; Zalcberg J.R.; Boussioutas A.; Findlay M.; Willis D.; Moore A.; Lordick F.; O'Callaghan C.; Swallow C.; Darling G.E.; Strickland A. ; Liberman M.; Mineur L.; Simes J.
9-Sep-2024Understanding factors influencing team functionality at operative vaginal birth through multidisciplinary perspectives.Kippen E.; Skinner D.S.M.; Mol D.B.W.; Rolnik D.D.L.; Kumar D.A.
10-Sep-2024Finding work-life balance in midwifery.Bayes S.; Buchanan D.K.; Dawson D.K.; Geraghty S.; Vukic D.; Bloxsome D.D.; Hay S.; Babatunde D.L.; Taylor J.
2-Sep-2024Impact of hyaluronic acid (HA) rectal spacer quality score (SQS) and fischer-valuck (FV) spacer symmetry score on rectal dosimetry and acute and late gastrointestinal (GI) toxicity outcomes - an Australian experience.Lin Y.H.; Lim Joon D.; Bolton D.; Chan Y.; Ho H.; McMillan K.; Manohar P. ; Koufogiannis G.; Foroudi F.; Tan A.; Cham C.W.; Pham T.; Liu M.; Davis A. ; Tacey M.; Chao M.W.T.
2-Sep-2024Stereotactic radiotherapy (SRT) with maintenance systemic therapy vs. standard-of-care (SOC) systemic therapy for oligoprogressive ER-positive, HER2-negative breast cancer (AVATAR-II).Connolly E.; White M. ; Siva S.; Bressel M.; Tan J.; Byrne K.; Day D. ; McCartney A. ; Webber K. ; David S.P.
9-Sep-2024Clinical practice guidelines for the care of girls and women with Turner syndrome Proceedings from the 2023 Aarhus International Turner Syndrome Meeting.Gravholt C.H.; Andersen N.H.; Christin-Maitre S.; Davis S.M.; Duijnhouwer A.; Gawlik A.; Maciel-Guerra A.T.; Gutmark-Little I.; Fleischer K.; Hong D.; Klein K.O.; Prakash S.K.; Shankar R.K.; Sandberg D.E.; Sas T.C.J.; Skakkebaek A.; Stochholm K.; van der Velden J.A.; Backeljauw P.F.; Alvarez-Nava F.; Avdic H.B.; Balle C.M.; Bamba V.; Bedei I.; Bonnard A.; Brickman W.J.; Brown N.M.; Chernausek S.; Cobbold J.; Corathers S.D.; Corpechot C.; Crenshaw M.L.; Davies M.; Deeb A.; Dessens A.; Dowlut-McElroy T.; Elliott V.; Fadoju D.; Fechner P.Y.; Geffner M.; Gitomer S.; de Groote K.; Hewitt J.; Ho C.; Hutaff-Lee C.; Isojima T.; Johannsen E.B.; Kawai M.; Keselman A.; Knickmeyer R.C.; Kremen J.; Kristrom B.; Kruszka P.; Law J.; Lin A.E.; Loechner K.; Mauras N.; Matthews D.; Mikkelborg T.; Mortensen K.H.; Nahata L.; Norman M.; Patel S.R.; Quigley C.; Ridder L.O.; Santen R.J.; Sheanon N.; Smyth A.; Turner H.; Verlinde F.; Viuff M.H.; Wasniewska M.; van der Weijde B.; Woelfle J.; Wolstencroft J.
22-Aug-2024Precision guided therapy provides clinical benefit in H3K27-altered diffuse midline glioma.McKay C.; Power P.; Staunton J.; Sriharan S.; Jessop S.; Zhukova N.; Trinder S.; Govender D.; Barahona P.; Gifford A.J.; Mignone C.; Xie A.; Tax G.; Tsoli M.; Dolman E.; Mayoh C.; Wong M.; Cowley M.; Marshall G.; Trahair T.; Lock R.B.; Ekert P.; Haber M.; Tyrell V.; Lau L.; Manoharan N.; Ziegler D.S.; Khuong-Quang D.-A.
Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 5565
 next >

Date issued